Study to be conducted by PharmaLegacy, a leading Contract Research Organization The scientific rationale for evaluating ...
Why aren't we talking about it more?
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly ...
Feb 18 (Reuters) - Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed ...
A common strep throat infection can trigger guttate psoriasis by altering the behavior of key immune cells, according to a new study from Karolinska Institutet published in eBioMedicine. The findings ...
Evidence from multiple trials links weight loss with milder symptoms and improved wellbeing in people with psoriasis.
Combination ixekizumab plus tirzepatide outperformed ixekizumab monotherapy for the treatment of both psoriasis and ...
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b ...
With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...
The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity ...
"Understanding biologic therapy trajectories in Medicaid is important, given its distinct formulary restrictions and patient demographics," they concluded. "Interventions must not only address access ...
Eli Lilly (LLY) stock is in focus as Zepbound succeeds in a late-stage trial for patients with plaque psoriasis. Read more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results